We are live on ! Find out more
RNTX

Rein Therapeutics
RNTX

22 hedge funds and large institutions have $2.37M invested in Rein Therapeutics in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

0% more funds holding

Funds holding: 22 → 22 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0.72% less ownership

Funds ownership: 1.35% → 0.64% (-0.72%)

54% less capital invested

Capital invested by funds: $5.2M → $2.37M (-$2.83M)

Holders
22
Holders Change
–
Holders Change %
0%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$99.4K
2
PVI
Pura Vida Investments
New York
+$93.8K
3
VF
Virtu Financial
New York
+$30.6K
4
Citadel Advisors
Citadel Advisors
Florida
+$8.69K
5
BlackRock
BlackRock
New York
+$7.03K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$1.47M
2
AC
Armistice Capital
New York
-$864K
3
SM
Sabby Management
Florida
-$319K
4
Jennison Associates
Jennison Associates
New York
-$142K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$69.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jennison Associates
1
Jennison Associates
New York
$1.23M -$142K -10,265 -10%
SM
2
Sabby Management
Florida
$368K -$319K -23,062 -46%
Renaissance Technologies
3
Renaissance Technologies
New York
$228K +$99.4K +7,185 +73%
Vanguard Group
4
Vanguard Group
Pennsylvania
$156K -$69.6K -5,030 -30%
PVI
5
Pura Vida Investments
New York
$91K +$93.8K +6,777 New
DCM
6
DAFNA Capital Management
California
$67K – – –
VF
7
Virtu Financial
New York
$45K +$30.6K +2,212 +195%
BlackRock
8
BlackRock
New York
$40K +$7.03K +508 +21%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$36K – – –
William Blair & Company
10
William Blair & Company
Illinois
$32K +$2.9K +210 +10%
JA
11
JOYN Advisors
Georgia
$20K – – –
HBWM
12
Hollow Brook Wealth Management
New York
$17K – – –
US Bancorp
13
US Bancorp
Minnesota
$17K – – –
Citadel Advisors
14
Citadel Advisors
Florida
$8K +$8.69K +628 New
Bank of America
15
Bank of America
North Carolina
$7K -$3.87K -280 -35%
KPW
16
Kore Private Wealth
New York
$5K – – –
Victory Capital Management
17
Victory Capital Management
Texas
$2K +$2.02K +146 New
BNP Paribas Financial Markets
18
BNP Paribas Financial Markets
France
$73 – – –
BBA
19
Baker Bros. Advisors
New York
– -$1.47M -102,000 Closed
AC
20
Armistice Capital
New York
– -$864K -60,000 Closed
Morgan Stanley
21
Morgan Stanley
New York
– -$21K -1,475 Closed
PAM
22
Panagora Asset Management
Massachusetts
– -$3K -175 Closed
Barclays
23
Barclays
United Kingdom
– +$55 +4 New
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
– +$429 +31 +3,100%

RNTX Hedge Fund Activity: Q3 2019 in Review

22 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q3 2019, worth a combined $2.37M — down 54% from $5.2M a quarter earlier.

Fund positioning in RNTX was balanced in Q3 2019: 4 funds opened new positions, 4 closed out, 5 added to existing stakes and 4 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $99.4K. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $1.47M sold.

  • 22 institutional investors held Rein Therapeutics (RNTX) as of Q3 2019, unchanged from Q2 2019.
  • Funds reported $2.37M of Rein Therapeutics stock for Q3 2019, down 54% quarter-over-quarter.
  • 4 funds opened new Rein Therapeutics positions in Q3 2019 and 4 closed out, a net change of 0 holders.
  • The largest Rein Therapeutics buyer in Q3 2019 was Renaissance Technologies, an estimated $99.4K added.
  • The largest Rein Therapeutics seller in Q3 2019 was Baker Bros. Advisors, an estimated $1.47M sold.

Based on aggregated 13F filings for Q3 2019.